PD-L1 in non-small-cell lung cancer: the third target for immunotherapy

Lancet. 2016 Apr 30;387(10030):1795-6. doi: 10.1016/S0140-6736(16)00700-5. Epub 2016 Mar 10.

Authors

Egbert F Smit¹, Michel M van den Heuvel²

Affiliations

¹ Department of Pulmonary Diseases, Vrije Universiteit VU Medical Center, 1007 MB Amsterdam, Netherlands; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: ef.smit@vumc.nl.
² Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.

PMID: 26972842
DOI: 10.1016/S0140-6736(16)00700-5

No abstract available

Publication types

Comment

MeSH terms

Antibodies / therapeutic use*
Antineoplastic Agents / therapeutic use*
B7-H1 Antigen / metabolism*
Carcinoma, Non-Small-Cell Lung*
Docetaxel
Female
Humans
Lung Neoplasms*
Male
Taxoids / therapeutic use*

Substances

Antibodies
Antineoplastic Agents
B7-H1 Antigen
CD274 protein, human
Taxoids
Docetaxel